Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?
about
The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy.Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapyPsoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.Treatment of Sarcoidosis.IL-22 is mainly produced by IFNγ-secreting cells but is dispensable for host protection against Mycobacterium tuberculosis infection.Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor-alpha inhibitor.Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.IL-10 modulates in vitro multinucleate giant cell formation in human tuberculosis.Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability.The safety of etanercept for the treatment of plaque psoriasis.Immunosuppression related to collagen-vascular disease or its treatment.Implications of TNF-α in the pathogenesis and management of GVHDEtanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.Tumor necrosis factor inhibitors and infection complications.Antibody therapeutics: isotype and glycoform selection.Tumor necrosis factor antagonists in the treatment of multicentric reticulohistiocytosis: Current clinical evidenceInduction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.Infliximab in the treatment of rheumatoid arthritisTuberculous peritonitis after treatment with adalimumab.Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.Immunopathogenesis of granulomas in chronic autoinflammatory diseases.Adalimumab induced pulmonary sarcoid reaction.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.New insights into gastrointestinal and hepatic granulomatous disorders.Development of lepromatous leprosy following etanercept treatment for arthritis.Listeriosis in patients receiving biologic therapies.Infection risk associated with anti-TNF-α agents: a review.State-of-the-art acute and chronic GVHD treatment.Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences.Advances in understanding the immunopathology of sarcoidosis and implications on therapy.Biologic therapies in the treatment of sarcoidosis.Death of a 29-Year-Old Male from Undifferentiated SepsisMycobacterium marinum: an increasingly common opportunistic infection in patients on infliximab.Tumour necrosis factor inhibitors and infection: What is there to know for infectious diseases physicians?New Insight into the Pathogenesis of Erythema Nodosum Leprosum: The Role of Activated Memory T-Cells.Granulomatous inflammation of pulmonary squamous cell carcinoma: a rare phenomenon.Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy.Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning treatment with infliximab.Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency.Visual recovery following Mycobacterium chelonae endophthalmitis.
P2860
Q33829772-0EFD8C4E-190B-4088-932C-AA1B1EE821BBQ33836681-C5A7A952-07DB-4893-8D62-D06167FF0D6DQ33939033-5B93C0D9-6372-4606-82F7-ECAE0723E1E8Q34477003-D9B849AD-0E42-46FC-90AB-3273BFFE46CCQ34608524-CE010D0B-1270-4250-A50E-8D12C9CB50A7Q34622449-28982ACE-26A3-49AA-ACC2-DE0663B5DD79Q34756501-B107A532-CD22-4972-8616-31F79CDDE7B2Q35023329-9771652B-3D76-44CE-A882-947569014213Q35851073-D3122269-193F-473B-B43A-7D4DF4982C4FQ35919214-80AB6849-52E0-42E0-A921-39CAB6AFB4BBQ36328708-DAB5533F-3E6C-4C2F-AE8D-E953D93D0E02Q36370782-E6DEDA39-1D79-461E-BA29-EAF431A40C8EQ36615576-0C7C8FAD-7974-45E6-A07B-8639FD8F0D22Q36806922-D1154394-8E6B-45FB-A859-64ABE3CB367FQ36922260-8D86B307-F56D-4419-B5D5-C6CB1CD09466Q37032241-A16650FB-769F-49FA-AB8D-8A6C6100C507Q37299387-874488B7-DDEE-4D02-B2CC-FCA86FB78F15Q37303230-1AB4F272-210D-46C8-8B70-3EE08B1A5046Q37315759-E22B0E17-D7DA-42F1-8C4B-475ADD41E146Q37473648-DC8475A4-F0C5-4BF1-9238-BEE236F277C2Q37538526-A778EC8B-816D-46C1-A8B1-092F6EE1A7D1Q37576496-CCB36FA8-4E5E-48F2-B471-9CA95A04F24BQ37810286-F0E1073C-D541-4305-AFB0-2F8B9F0A32E6Q37911957-DEA8951C-E3B6-4292-B1E9-B74D4E9920BEQ37968490-1C88798A-031F-4AC6-AC00-516EFB9FEC55Q38097376-F838D935-99D8-4C4A-9E6A-0AA07913A9FAQ38335718-D2749AE2-1801-4746-A2A6-1EC20F62089EQ38416376-6AE22950-065B-4FEA-98F3-E59ABCDE6161Q38673326-5B4E46DB-58B5-412A-9183-222EBD248E92Q38814035-D5B4E055-1100-47D7-A1FF-CD0410AA5697Q38818458-0224B5ED-E516-45B1-8A54-62D2327F5C83Q38846431-55E52E91-DF60-4733-9BDD-300E0BB20635Q38872793-1DEA6E5F-FA3F-4E64-A142-3CA1E7298864Q40672157-F1A11ABF-1A26-450A-A50B-9E2A8EEC488CQ41665221-5A8A2385-BB7A-4573-90E2-0233525189B4Q41963945-76F39A29-7D0A-41E0-A6E9-7C143B2D023CQ42504159-0A46BF2D-8452-4B76-947E-EDECC487C4E6Q43450427-6D9A5E76-7AFB-4A6C-8D38-DF0E76150331Q43793814-BC6D5074-7914-4D99-AD5A-3EB477C4E1D2Q44434193-9C7192CF-EBB7-456D-8BD2-9EAFC7C88983
P2860
Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Tumor necrosis factor and its ...... of infliximab and etanercept?
@en
Tumor necrosis factor and its ...... of infliximab and etanercept?
@nl
type
label
Tumor necrosis factor and its ...... of infliximab and etanercept?
@en
Tumor necrosis factor and its ...... of infliximab and etanercept?
@nl
prefLabel
Tumor necrosis factor and its ...... of infliximab and etanercept?
@en
Tumor necrosis factor and its ...... of infliximab and etanercept?
@nl
P2860
P356
P1476
Tumor necrosis factor and its ...... of infliximab and etanercept?
@en
P2093
Stefan Ehlers
P2860
P304
P356
10.1086/429998
P407
P478
41 Suppl 3
P577
2005-08-01T00:00:00Z